Abstract
Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumour-infiltrating lymphocytes (TILs) from a patient with metastatic cholangiocarcinoma contained CD4+ T helper 1 (TH1) cells, recognizing a mutation in the erbb2 interacting protein (ERBB2IP) expressed by the cancer. After adoptive transfer of TILs, containing about 25% mutation-specific polyfunctional TH1 cells, the patient achieved a decrease in target lesions with prolonged stabilization of the disease. Upon disease progression, the patient was retreated with a >95% pure population of mutation-reactive TH1 cells and again experienced tumour regression. These results provide evidence that a CD4+ T cell response against a mutated antigen can be harnessed to mediate regression of a metastatic epithelial cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1175-1177 |
| Number of pages | 3 |
| Journal | Journal of Hepatology |
| Volume | 61 |
| Issue number | 5 |
| Early online date | 30 Jun 2014 |
| DOIs | |
| Publication status | Published - 1 Nov 2014 |
Keywords
- cancer
- Immunology
- tumour infiltrating lymphocytes
Access to Document
- Bertoletti_Cancer_immunotherapy_International_Hepatology_2014
NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, Vol 61, Issue 5, November 2014, DOI: 10.1016/j.jhep.2014.06.023. Eligibility for repository checked February 2015